

#21

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Roger W. Roeske

Serial No.: 08/480,494

Filed: June 7, 1995

For: *LHRH ANTAGONIST PEPTIDES*

Attorney Docket No.: PPI-007

Group Art Unit: T8T1

Examiner: Borin, M.

RECEIVED

AUG 20 1997

MATRIX CUSTOMER  
SERVICE CENTER

**VIA HAND DELIVERY**

Assistant Commissioner for Patents  
Washington, D.C. 20231

**SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

Applicant and his agent are aware of the following publications and information, listed on the attached PTO Form 1449, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration. A full copy of each cited publication is enclosed.

With regard to reference DL, which is in German, Applicant's understanding of the relevance of this document is based on the English language abstract provided on the first page of the document, which discloses LHRH antagonists of a general formula shown in the abstract.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicant understands that the Examiner will make an independent evaluation of the cited publications.

Under 37 C.F.R. § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the

merits issues in this application bearing a mailing date prior to the date of this Second Supplemental Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR 1.17(p) to our Deposit Order Account No. 12-0080.

In view of the large number of references that have been made of record in this application by way of 1) the Information Disclosure Statement dated March 5, 1996; 2) the Supplemental Information Disclosure Statement dated April 11, 1997; and 3) the instant Second Supplemental Information Disclosure Statement, Applicant would like to draw the Examiner's attention in particular to the following cited references:

- 1) U.S. Patent No. 5,110,904 (Reference BV);
- 2) U.S. Patent No. 5,300,492 (Reference CC);
- 3) U.S. Patent No. 5,413,990 (Reference CF);
- 4) U.S. Patent No. 4,800,191 (Reference DA);
- 5) U.S. Patent No. 5,198,533 (Reference DB); and
- 6) U.S. Patent No. 5,491,217 (Reference DF).

If a telephone conversation with Applicant's Agent would expedite the prosecution of the above-identified application, the examiner is urged to call the undersigned at (617) 227-7400.

Respectfully submitted,



Catherine J. Kara  
Reg. No. 41,106  
Agent for Applicant

LAHIVE & COCKFIELD, LLP  
28 State Street  
Boston, MA 02109  
(617) 227-7400

Date: August 19, 1997

# LAHIVE & COCKFIELD, LLP

JOHN A. LAHIVE, JR. (1928-1997)  
W. HUGO LIEPMANN  
JAMES E. COCKFIELD  
THOMAS V. SMURZYNSKI  
RALPH A. LOREN  
THOMAS J. ENGELLENER  
GIULIO A. DeCONTI, JR.  
ANN LAMPORT HAMMITTE  
PAUL LOUIS MYERS, Ph.D.  
ELIZABETH A. HANLEY  
MICHAEL I. FALKOFF  
JOHN V. BIANCO  
AMY BAKER MANDRAGOURAS  
ANTHONY A. LAURENTANO  
JANE E. REMILLARD  
MARK A. KURISKO  
JEAN M. SILVERI  
PETER J. RAINVILLE  
CHARLES ERIC SCHULMAN  
FAUSTINO A. LICAUCO

COUNSELLORS AT LAW  
28 STATE STREET  
BOSTON, MASSACHUSETTS 02109  
TELEPHONE (617) 227-7400  
FAX (617) 742-4214  
lc@lahcoc.com

SCOTT D. ROTHENBERGER, Ph.D.  
DAVID A. LANE, JR.  
THOMAS P. GRODT

OF COUNSEL  
JEREMIAH LYNCH  
LAWRENCE E. MONKS  
WILLIAM A. SCOFIELD, JR.

TECHNICAL SPECIALISTS  
CATHERINE J. KARA, Ph.D.  
MARK D. RUSSETT  
IVANA MARAVIC-MAGOVCEVIC, Ph.D.  
MEGAN E. WILLIAMS, Ph.D.  
SONIA K. GUTERMAN, Ph.D.  
DIANA M. COLLAZO, Ph.D.  
JASSIR K. SAGOO, Ph.D.  
DEBRA J. MILASINCIC, Ph.D.  
MARIA C. LACCOTRIPE, Ph.D.  
LAURANNE S. BUTLER

August 19, 1997

## VIA HAND DELIVERY

Assistant Commissioner for Patents  
Washington, D.C. 20231

RECEIVED

Re: U.S. Patent Application Serial No. 08/480,494  
*LHRH ANTAGONIST PEPTIDES*  
by: Roger W. Roeske  
Filed: June 7, 1995  
Our Ref. No.: PPI-007

MATRIX CUSTOMER  
SERVICE CENTER

Dear Sir:


I enclose herewith for filing in the above-identified application the following:

1. Second Supplemental Information Disclosure Statement;
2. PTO Form 1449;
3. Full copies of references (7) cited in PTO Form 1449; and
4. Postcard Receipt.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

Respectfully submitted,

LAHIVE & COCKFIELD, LLP



Catherine J. Kara  
Registration No. 41,106  
Agent for Applicant